A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Brunet J, Choucha Z, Gransagne M, Tabbal H, Ku M-W, Buchrieser J, Fernandes P, Batalie D, Lopez J, Ma L, Dufour E, Simon E, Hardy D, Petres S, Guinet F, Strick-Marchand H, Monot M, Charneau P, Majlessi L, Duprex WP, Gerke C, Martin A, Escriou N.
Brunet J, et al. Among authors: simon e.
J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693-23. Online ahead of print.
J Virol. 2024.
PMID: 38563763
Free article.